好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

MRI Morphometry in Early Multiple System Atrophy: Correlations with Indices of Disease Burden & Tracking Progression
Neuromuscular and Clinical Neurophysiology (EMG)
P3 - Poster Session 3 (5:30 PM-6:30 PM)
7-050

Our goal was to examine i) associations between MRI features and indices of disease burden and ii) utility of these features for longitudinal tracking of disease progression.

Recently, we identified key MRI morphometric changes in early disease stages of multiple system atrophy (MSA) - brainstem, cerebellar white matter (WM), and striatum. 

We prospectively enrolled possible or probable MSA patients whose disease was still relatively early (unified multiple system atrophy rating scale [UMSARS] I: 5-16 and able to walk unaided) to undergo standardized T1 MPRAGE images on 3 T MRI scanners for morphometric MRI analysis. There were 17 early MSA (9 MSA-C and 8 MSA-P) and 15 normal subjects with MRI scans at baseline and a subset with follow-up scans at 12-months.  MRI volumes were computed using Freesurfer v5.3 and scaled to head size. Indices of disease burden included symptom and functional deficit scale (UMSARS I), motor deficit scale (UMSARS II), autonomic deficit scale (CASS+TST), and autonomic symptom score (COMPASS).

All MSA specific regions strongly correlated with both UMSARS I and UMSARS II (r=-0.63 to -0.65, p<0.001) with these regions explaining over 50% of the variability.  CASS+TST had stronger correlation with striatum (r=-0.58, p<0.001) compared to correlations with brainstem (r=-0.43, p=0.015) and cerebellar WM (r=-0.47, p=0.006). COMPASS was only associated with striatum volume (r=-0.58, p<0.001). There was a marked decrease in MSA specific regional volumes over one-year period for both brainstem and cerebellar WM in MSA, which was not seen in controls. There was also significant decrease in MSA-P observed in the striatum volume.

MRI morphometry of selected brain regions was strongly associated with measures of disease severity in MSA and tracks with progression of volume loss over time, supporting its role as a surrogate marker of disease progression for future clinical trials in MSA.
Authors/Disclosures
Prashanthi Vemuri, PhD (Mayo Clinic)
PRESENTER
The institution of Dr. Vemuri has received research support from NIH.
Anna Castillo Anna Castillo has nothing to disclose.
Kaely Thostenson No disclosure on file
No disclosure on file
No disclosure on file
Tonette Gehrking Tonette Gehrking has nothing to disclose.
Jade Gehrking (Mayo Clinic, Neurology Dept) Jade Gehrking has nothing to disclose.
No disclosure on file
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
Phillip A. Low, MD, FAAN (Mayo Clinic) Dr. Low has nothing to disclose.
Wolfgang Singer, MD, FAAN (Mayo Clinic) Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. The institution of Dr. Singer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Yoda. Dr. Singer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Singer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ferrer. The institution of Dr. Singer has received research support from NIH. The institution of Dr. Singer has received research support from FDA. The institution of Dr. Singer has received research support from Michael J. Fox Foundation. Dr. Singer has received intellectual property interests from a discovery or technology relating to health care.